PORT HUENEME, CA--(Marketwire - January 25, 2011) - Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce successful completion of preclinical toxicity and immunogenicity testing of Stellar KLH/IMG and Stellar Subunit KLH in rodent and non-rodent species. These early tests support key, new product ideas put forward by the Company.